Cohort Studyhigh evidence
Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.
Circulation·August 18, 2026·PMID 42610271
Why it mattersInflammation is a key driver of residual cardiovascular risk in patients with established atherosclerotic disease, even with optimal medical therapy. This analysis provides mechanistic insight into how semaglutide reduces MACE beyond weight loss and glucose control, potentially identifying hsCRP as a biomarker for monitoring treatment response and selecting patients who may derive the greatest benefit.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled